CorFlow

About

CorFlow Therapeutics is a Swiss medtech company based in Baar, Switzerland, founded in 2016. The company specializes in diagnostic and therapeutic solutions aimed at restoring healthy microvascular blood flow, particularly focusing on microvascular obstruction (MVO) in heart attack patients during percutaneous coronary intervention (PCI). CorFlow is committed to leading innovations in microvascular blood flow restoration, with a primary emphasis on improving outcomes for STEMI patients. The company's flagship product is the Controlled Flow Infusion (CoFI™) System, designed for real-time diagnosis and treatment of MVO during PCI. This system offers accurate MVO detection comparable to cardiac MRI, provides rapid diagnostic results, and integrates seamlessly into PCI workflows. CorFlow holds 15 patents related to cardiology and has a leadership team with extensive experience in the MedTech field, including backgrounds in vascular and interventional cardiology.